Apyx Medical (BOV) Stock Forecast & Price Target

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

BOV Analyst Ratings

Strong Buy

3 Buy

0 Hold

0 Sell

Based on 3 analysts giving stock ratings to

Apyx

Medical

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

BOV Stock 12 Month Forecast

Average Price Target

€5.50

▲(66.56% Upside)

Based on 3 Wall Street analysts offering 12 month price targets for Apyx Medical in the last 3 months. The average price target is €5.50 with a high forecast of €6.08 and a low forecast of €5.21. The average price target represents a 66.56% change from the last price of €3.30.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","7":"€7","1.75":"€1.75","3.5":"€3.5","5.25":"€5.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":6.0751601399999995,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€6.08</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.4965734600000005,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€5.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.20728012,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€5.21</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,1.75,3.5,5.25,7],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.52,3.71655078,3.91310156,4.10965234,4.30620312,4.5027539,4.69930468,4.89585546,5.09240624,5.28895702,5.4855078,5.68205858,5.87860936,{"y":6.0751601399999995,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.52,3.6720441123076926,3.8240882246153847,3.976132336923077,4.12817644923077,4.280220561538462,4.432264673846154,4.584308786153846,4.736352898461539,4.888397010769231,5.040441123076923,5.192485235384616,5.344529347692308,{"y":5.4965734600000005,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.52,3.6497907784615387,3.779581556923077,3.9093723353846155,4.039163113846154,4.168953892307693,4.2987446707692305,4.428535449230769,4.558326227692308,4.688117006153846,4.817907784615384,4.947698563076923,5.077489341538461,{"y":5.20728012,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.61,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.63,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.75,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.44,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.36,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.9,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.3,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.68,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.14,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.88,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.36,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.86,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.52,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€6.08

Average Price Target€5.50

Lowest Price Target€5.21

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Sam Eiber

BTIG

€5.21

Buy

57.80%

Upside

Reiterated

08/07/26

Apyx Medical (APYX) Receives a Buy from BTIG

Yi Chen

H.C. Wainwright

€6.08

Buy

84.10%

Upside

Reiterated

08/07/26

Apyx Medical Maintained at Buy on Strong Growth and AYON Momentum; Yi Chen Keeps $7 Price Target Unchanged

Matt Hewitt

Craig-Hallum

€5.21

Buy

57.80%

Upside

Reiterated

05/08/26

Apyx Medical (APYX) Gets a Buy from Craig-Hallum

Kyle Bauser

Roth MKM

€5.21

Buy

57.80%

Upside

Reiterated

04/14/26

Apyx Medical (APYX) Receives a Buy from Roth MKM

David Turkaly

Citizens JMP

€6.94

Buy

110.40%

Upside

Upgraded

11/12/25

Apyx Medical upgraded to Outperform from Market Perform at Citizens JMPApyx Medical upgraded to Outperform from Market Perform at Citizens JMP

Alex Fuhrman

Lucid Capital

€3.47

Buy

5.20%

Upside

Initiated

10/06/25

Apyx Medical (APYX) Receives a New Rating from Lucid Capital

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Sam Eiber

BTIG

€5.21

Buy

57.80%

Upside

Reiterated

08/07/26

Apyx Medical (APYX) Receives a Buy from BTIG

Yi Chen

H.C. Wainwright

€6.08

Buy

84.10%

Upside

Reiterated

08/07/26

Apyx Medical Maintained at Buy on Strong Growth and AYON Momentum; Yi Chen Keeps $7 Price Target Unchanged

Matt Hewitt

Craig-Hallum

€5.21

Buy

57.80%

Upside

Reiterated

05/08/26

Apyx Medical (APYX) Gets a Buy from Craig-Hallum

Kyle Bauser

Roth MKM

€5.21

Buy

57.80%

Upside

Reiterated

04/14/26

Apyx Medical (APYX) Receives a Buy from Roth MKM

David Turkaly

Citizens JMP

€6.94

Buy

110.40%

Upside

Upgraded

11/12/25

Apyx Medical upgraded to Outperform from Market Perform at Citizens JMPApyx Medical upgraded to Outperform from Market Perform at Citizens JMP

Alex Fuhrman

Lucid Capital

€3.47

Buy

5.20%

Upside

Initiated

10/06/25

Apyx Medical (APYX) Receives a New Rating from Lucid Capital

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

TNYATenaya Therapeutics

JBIOJade Biosciences

GHRSGH Research

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Apyx Medical

3 Months

David TurkalyCitizens JMP

Success Rate

10/18 ratings generated profit

Average Return

+9.14%

Copying David Turkaly's trades and holding each position for 3 Months would result in 55.56% of your transactions generating a profit, with an average return of +9.14% per trade.

1 Year

Matt HewittCraig-Hallum

Success Rate

16/29 ratings generated profit

Average Return

+40.43%

Copying Matt Hewitt's trades and holding each position for 1 Year would result in 55.17% of your transactions generating a profit, with an average return of +40.43% per trade.

2 Years

Matt HewittCraig-Hallum

Success Rate

21/29 ratings generated profit

Average Return

+90.82%

Copying Matt Hewitt's trades and holding each position for 2 Years would result in 72.41% of your transactions generating a profit, with an average return of +90.82% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BOV Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, BOV has received 3 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. BOV average Analyst price target in the past 3 months is 5.50.

Each month's total comprises the sum of three months' worth of ratings.

BOV Financial Forecast

BOV Earnings Forecast

Next quarter’s earnings estimate for BOV is -€0.08 with a range of -€0.10 to -€0.05. The previous quarter’s EPS was -€0.06. BOV beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 41.04% of the time in the same period. In the last calendar year BOV has Performed in-line its overall industry.

BOV Sales Forecast

Next quarter’s sales forecast for BOV is €11.89M with a range of €11.22M to €12.24M. The previous quarter’s sales results were €12.05M. BOV beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.07% of the time in the same period. In the last calendar year BOV has Performed in-line its overall industry.

BOV Stock Forecast FAQ

What is DE:BOV’s average 12-month price target, according to analysts?

Based on analyst ratings, Apyx Medical Corporation’s 12-month average price target is 5.50.

What is DE:BOV’s upside potential, based on the analysts’ average price target?

Apyx Medical Corporation has 66.56% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Apyx Medical Corporation a Buy, Sell or Hold?

Apyx Medical Corporation has a consensus rating of Strong Buy, which is based on 3 buy ratings, 0 hold ratings and 0 sell ratings.

What is Apyx Medical Corporation’s share price target?

The average share price target for Apyx Medical Corporation is 5.50. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €6.08 ,and the lowest forecast is €5.21. The average share price target represents 66.56% Increase from the current price of €3.3.

What do analysts say about Apyx Medical Corporation?

Apyx Medical Corporation’s analyst rating consensus is a Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.

How can I buy shares of Apyx Medical Corporation?

To buy shares of DE:BOV, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Apyx Medical (BOV) Stock Forecast & Price Target

BOV Analyst Ratings

BOV Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Apyx Medical

BOV Analyst Recommendation Trends

BOV Financial Forecast

BOV Earnings Forecast

BOV Sales Forecast

BOV Stock Forecast FAQ

Detailed List of Analyst Forecasts